Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Share-based Compensation (2020 - 2025)

Maxcyte (MXCT) has disclosed Share-based Compensation for 6 consecutive years, with $706000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 77.47% to $706000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, down 29.58% year-over-year, with the annual reading at $9.2 million for FY2025, 29.58% down from the prior year.
  • Share-based Compensation for Q4 2025 was $706000.0 at Maxcyte, down from $2.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $3.6 million in Q3 2023, with the low at $706000.0 in Q4 2025.
  • Average Share-based Compensation over 5 years is $2.8 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Share-based Compensation surged 282.17% in 2021, then plummeted 77.47% in 2025.
  • Over 5 years, Share-based Compensation stood at $2.4 million in 2021, then grew by 27.36% to $3.1 million in 2022, then grew by 14.62% to $3.6 million in 2023, then dropped by 12.31% to $3.1 million in 2024, then tumbled by 77.47% to $706000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $706000.0, $2.0 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.